Prime Medicine Secures NZ Clearance for PM577a Targeting H1069Q Mutation
PRME•Prime Medicine secured New Zealand Medsafe approval for its clinical trial application of PM577a, targeting the ATP7B H1069Q mutation in Wilson Disease, marking the first in vivo Prime Editing authorization. The global Phase 1/2 trial will commence in H2 2026 with initial proof-of-concept data expected in 2027.
1. New Zealand Clearance of PM577a Trial
Medsafe clearance in New Zealand marks the first clinical authorization for an in vivo Prime Editing therapy from Prime Medicine, enabling a global Phase 1/2 study of PM577a in patients with the H1069Q ATP7B mutation.
2. Phase 1/2 Trial Design and Timeline
The open-label, ascending-dose study will enroll adults and adolescents with Wilson Disease who are stable on standard therapy. Dosing will begin in the second half of 2026, with safety, tolerability and biological activity assessed via 64Cu PET copper efflux, serum ceruloplasmin, non-ceruloplasmin bound copper, urinary copper excretion and hepatic biopsy; initial clinical data are targeted for 2027.
3. PM577 Platform and Follow-On Candidates
PM577a is formulated in a lipid nanoparticle delivery system designed for a one-time intravenous infusion that precisely edits the ATP7B gene. A follow-on candidate targeting the R778L mutation prevalent in East Asian patients is in preclinical development, leveraging the same modular platform for rapid expansion.
4. Wilson Disease Market and Impact
Wilson Disease affects roughly 1 in 30,000 individuals, with no approved curative options and high non-adherence to chelators. A successful one-time genomic therapy could capture a significant share of the market constrained by lifelong treatment burdens and limited liver transplant availability.
